2020-000585-41: A clinical study to investigate tregalizumab effects on allergen-induced airway responses and airway inflammation in asthmatic patients |
|
|
| Not yet recruiting | 2 | 42 | Europe | Tregalizumab 100 mg/mL, Provokit® 0,33%, BT061, Solution for injection, Powder and solvent for nebuliser solution, Provokit® 0,33% | T-Balance Therapeutics GmbH, T-Balance Therapeutics GmbH | mild controlled allergic asthma and house-dust mite (HDM) allergy, allergic asthma and house-dust mite allergy, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |